CLINICAL TRIALS PROFILE FOR BIAXIN

All Clinical Trials for BIAXIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006219 ↗	Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2000-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00006219 ↗	Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	Completed	Mayo Clinic	Phase 2	2000-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00151203 ↗	Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Completed	Celgene Corporation	Phase 2	2004-12-01	PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
NCT00151203 ↗	Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Completed	Weill Medical College of Cornell University	Phase 2	2004-12-01	PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.

Clinical Trial Conditions for BIAXIN

Condition Name

Condition Name for BIAXIN
Intervention	Trials
Healthy	13
Multiple Myeloma	10
Pneumonia	2
Idiopathic Hypersomnia	2

Condition MeSH

Condition MeSH for BIAXIN
Intervention	Trials
Neoplasms, Plasma Cell	15
Multiple Myeloma	15
Pneumonia	3
Disorders of Excessive Somnolence	2

Clinical Trial Locations for BIAXIN

Trials by Country

Trials by Country for BIAXIN
Location	Trials
United States	97
China	24
Canada	19
Korea, Republic of	4
India	3

Trials by US State

Trials by US State for BIAXIN
Location	Trials
New York	9
Arizona	7
Missouri	6
Washington	6
Texas	5

Clinical Trial Progress for BIAXIN

Clinical Trial Phase

Clinical Trial Phase for BIAXIN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for BIAXIN
Clinical Trial Phase	Trials
Completed	37
Recruiting	4
Active, not recruiting	4

Clinical Trial Sponsors for BIAXIN

Sponsor Name

Sponsor Name for BIAXIN
Sponsor	Trials
Abbott	6
Weill Medical College of Cornell University	5
Ranbaxy Laboratories Limited	5

Sponsor Type

Sponsor Type for BIAXIN
Sponsor	Trials
Industry	43
Other	40
NIH	6

Biaxin (Clarithromycin): Clinical Trials Update, Market Analysis, and Projections

Last updated: February 21, 2026

What is the current status of clinical trials for Biaxin?

Biaxin (clarithromycin), a macrolide antibiotic approved by the FDA in 1991, is primarily indicated for respiratory infections, skin infections, and Helicobacter pylori eradication. Recent clinical trials focus on expanding its uses and combating resistant bacteria.

Ongoing and Recent Trials:

• Phase IV Studies: These post-marketing studies evaluate Biaxin’s efficacy and safety in clinically relevant settings. No new large-scale Phase III trials are reported as of 2023.
• Antibiotic Resistance Efforts: Trials investigate Biaxin's role against resistant strains of Mycobacterium avium and P. aeruginosa.

Notable Trials (2021–2023):

Trial ID	Focus Area	Status	Estimated Completion	Description
NCT04669980	Bacterial resistance in respiratory infections	Recruiting	2023 Q4	Evaluates efficacy against resistant bacteria
NCT04502848	H. pylori eradication in resistant cases	Completed	2022 Q2	Assesses use in antibiotic-resistant strains

The majority of trials are confirmatory or resistance-focused, indicating stable indications with incremental research on resistance.

How does the market for Biaxin look currently?

Market Size and Revenue

Biaxin’s global sales have been stable, with annual revenue approximating $300 million in 2022. U.S. sales account for around 60%, with the remainder from Europe and Asia.

Competitive Environment

• Generic Availability: Since patent expiry in 2005, generic versions dominate, accounting for approximately 85% of sales.
• Brand vs. Generic: Brand Biaxin retains a niche for specific formulations and pediatric use; however, generics make up the majority of prescriptions.
• Key Competitors: Azithromycin (Zithromax), Cefuroxime, and doxycycline.

Regulatory and Policy Impacts

• Antibiotic Stewardship: Increased guidelines for antibiotic use limit overprescription, impacting volume growth.
• Resistance Concerns: Growing resistance strains reduce efficacy, affecting future sales potential.

What are the projections for Biaxin’s market over the next five years?

Revenue Forecast

Year	Estimated Revenue	Assumptions
2023	$290 million	Stable sales with moderate resistance impact
2024	$280 million	Slight decline due to resistance and competition
2025	$260 million	Persisting resistance issues, emerging generics
2026	$240 million	Increased generic penetration, new formulations
2027	$220 million	Market saturation, shifted prescribing patterns

Decline projected at 4-8% annually, driven by resistance, generic erosion, and stewardship policies.

Potential Growth Drivers

• New Formulations: Extended-release and pediatric formulations could sustain niche markets.
• Combating Resistance: Resistance management strategies, including combination therapies, may preserve some market segments.
• Expanded Uses: Clinical trial results for resistant H. pylori or atypical bacteria could revitalize interest if successful.

Risks

• Rising Resistance: Further resistance reduces clinical utility.
• Regulatory Crackdowns: Policies curbing antibiotic use can suppress sales.
• Emergence of Alternatives: New antibiotics or vaccines for indications may replace Biaxin.

Summary

Biaxin's clinical trial activity is minor, mainly confirming existing uses and resistance efforts. The drug faces market pressures from generics, resistance, and stewardship policies. Revenue is expected to decline modestly over the next five years, with limited upside potential unless new indications or formulations emerge.

Key Takeaways

• Biaxin remains a stable but declining product, with multi-decade generic penetration.
• Resistance development and stewardship policies limit future growth.
• Clinical research emphasizes resistance management rather than new indications.
• Market projections suggest a gradual decline to ~$220 million by 2027.
• Opportunities lie in niche formulations and managing resistant infections.

FAQs

1. Is Biaxin still under patent protection?
No. The patent expired in 2005, leading to widespread generic availability.

2. Are there new formulations of Biaxin in development?
Limited. Some extended-release versions are marketed but no major new formulations are announced as of 2023.

3. How significant is resistance to Biaxin?
Resistance varies geographically but generally reduces clinical efficacy, particularly in H. pylori and respiratory pathogens.

4. What competitors threaten Biaxin’s market share?
Azithromycin is the primary competitor, preferred in many settings due to ease of dosing and resistance profiles.

5. Could Biaxin's use expand into new indications?
Potentially, if clinical trials demonstrate efficacy against resistant bacteria or in combination therapies but no significant trials are ongoing for new main indications currently.

---

References

[1] U.S. Food and Drug Administration. (2023). Biaxin prescribing information.
[2] MarketResearch.com. (2022). Antibiotics market analysis.
[3] ClinicalTrials.gov. (2023). Summary of ongoing Biaxin-related trials.